ArticleCardiology journal2025
Preclinical safety and performance evaluation of a highly-flexible peripheral polytetrafluoroethylene-covered stent.
Article in Cardiology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSten graft implantation faces challenges such as deliverability issues, fracture risk, and subsequent restenosis. Recent advancements have introduced thinner coatings for increased flexibility and improved biocompatibility. The aim herein was to assess the safety and performance of a highly flexible cobalt-chromium stent covered with polytetrafluoroethylene (PTFE) in a preclinical model.
methodsIn total 6 PTEF-covered stent grafts 6mm x 38mm cobalt-chromium, (Solaris BXTM, Scitech Produtos Medicos) were implanted compared to 5 controls ( BeGraftTM, Bentley InnoMed GmbH) in the iliac arteries of 11 swine. Stents were evaluated with angiography, high-definition IVUS, and histology for 28 days.
resultsAll animals underwent successful implantation with 100% survival at follow-up. At 28 days, there was no statistically significant difference in MLD compared to baseline in both groups (test, 5.2 ± 0.7 mm vs 5.3 ± 0.6 mm, p = 0.8; control, 4.9 ± 0.7 mm vs 5.1 ± 0.5 mm, p = 0.8), indicating no LLL (test, -0.2 ± 0.16 vs control, -0.18 ± 0.16 mm; p = 0.8). IVUS revealed a tendency for the less neointimal area in the test group (3.75 ± 0.9mm² vs 5.69 ± 2.2 mm²; p = 0.08), resulting in a tendency toward higher % AS in the control arm (14.07 ± 3.42% vs 20 ± 7%; p = 0.1). Microscopic evaluation revealed minimal vascular injury (test 0.1 ± 0.3 vs control 0.1 ± 0.1) and complete endothelialization coverage (test, 3.2 ± 0.8 vs control 3.8 ± 0.3) in both groups, with minimal inflammation(test vs. control: per strut 0.02 ± 0.06 vs. 0.14 ± 0.22; neointimal 1.2 ± 0.6 vs 1.1 ± 0.4; medial 0.3 ± 0.4 vs 0.3 ± 0.4).
conclusionSolaris BXTM demonstrated highly flexible and biocompatible, with minimal vascular injury, and reduced neointimal hyperplasia compared to the control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.